Antisense protein kinase a RIα-induced tumor reversion: Portrait of a microarray

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1697, Issue 1-2, 2004, Pages 71-79

  Cho Chung, Yoon S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antisense; C; cAMP; Cancer; Catalytic subunit of PKA; cDNA; Chemotherapy; Complementary DNA; Cyclic AMP; DNA microarray; EGFR; Epidermal growth factor receptor; Gene expression; Growth inhibition; MBO; Mixed backbone oligonucleotide; Oligonucleotide; Protein kinase A

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CAPECITABINE; CARBOPLATIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DACARBAZINE; DOCETAXEL; GEMCITABINE; GENE EXPRESSION MODULATOR 231; GTI 2040; IRINOTECAN; ISIS 2503; ISIS 3521; LR 3001; MG 98 B; OBLIMERSEN; PACLITAXEL; UNCLASSIFIED DRUG;

CANCER PREVENTION; CLINICAL TRIAL; CONFERENCE PAPER; DNA MICROARRAY; DRUG INHIBITION; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; GROWTH INHIBITION; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DNA, COMPLEMENTARY; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OLIGONUCLEOTIDES, ANTISENSE; PHENOTYPE; UP-REGULATION;

EID: 1542298992     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2003.11.014     Document Type: Conference Paper

References (61)

1. Zamecnik P., Stephenson M. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. U. S. A. 75:1978;280-284.
2. Agrawal S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol. 14:1996;376-387.
3. Agrawal S. Antisense Therapeutics. 1996;Humana Press, New Jersey.
4. Akhtar S., Agrawal S. In vivo studies with antisense oligonucleotides. Trends Pharmacol. Sci. 18:1997;12-18.
5. Bennett C.F. Antisense oligonucleotides: is the glass half full or half empty? Biochem. Pharmacol. 55:1998;9-19.
6. Stein C.A., Krieg A.M. Applied Antisense Oligonucleotide Technology. 1998;Wiley-Liss, New Jersey.
7. Stein C., Cheng Y.-A. Antisense inhibition of gene expression. DeVita V., Rosenberg S.A., Hellman S. Principles and Practice of Oncology. 1997;3059-3074 Lippincott, New York.
8. Crooke S.T. Antisense Research and Application. 1998;Springer, New York.
9. Wickstrom E. Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors. 1998;Marcel Dekker, New York.
10. Nesterova M., Cho-Chung Y.S. A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth. Nat. Med. 1:1995;528-633.
11. Cho-Chung Y.S. Antisense DNAs as targeted therapeutics for cancer: no longer a dream. Curr. Opin. Investig. Drugs. 3:2002;934-939.
12. Dorr F. Antisense oligonucleotides in the treatment of cancer. Antisense Nucleic Acid Drug Dev. 9:1999;391-396.
13. Cho-Chung Y.S. Antisense and therapeutic oligonucleotides: toward a gene-targeting cancer clinic. Expert Opin. Ther. Pat. 10:2000;1711-1724.
14. Gewirtz A.M. Oligonucleotide therapeutics: a step forward. J. Clin. Oncol. 18:2000;1809-1811.
15. Tamm I., Dorken B., Hartmann G. Antisense therapy in oncology: new hope for an old idea? Lancet. 358:2001;489-497.
16. Uhlmann E. Oligonucleotide technologies: synthesis, production, regulations and applications. 29-30th November 2000, Hamburg, Germany. Expert Opin. Biol. Ther. 1:2001;319-328.
17. Dove A. Antisense and sensibility. Nat. Biotechnol. 20:2002;121-124.
18. Agrawal S., Jiang Z., Zhao Q., Shaw D., Cai Q., Roskey A., Channavajjala L., Saxinger C., Zhang R. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc. Natl. Acad. Sci. U. S. A. 94:1997;2620-2625.
19. Agrawal S., Zhao Q. Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev. 8:1998;135-139.
20. Agrawal S., Zhao Q. Antisense therapeutics. Curr. Opin. Chem. Biol. 2:1998;519-528.
21. Nesterova M., Cho-Chung Y.S. Oligonucleotide sequence-specific inhibition of gene expression, tumor growth inhibition, and modulation of cAMP signaling by an RNA-DNA hybrid antisense targeted to protein kinase A RIα subunit. Antisense Nucleic Acid Drug Dev. 10:2000;423-433.
22. Cho-Chung Y.S., Nesterova M., Pepe S., Lee G.R., Noguchi K., Srivastava R.K., Srivastava A.R., Alper O., Park Y.G., Lee Y.N. Antisense DNA-targeting protein kinase A-RIα subunit: a novel approach to cancer treatment. Front. Biosci. 4:1999;D898-D907.
23. Krebs E.G. Protein kinases. Curr. Top. Cell. Regul. 5:1972;99-133.
24. Beebe S.J., Corbin J.D. Cyclic nucleotide-dependent protein kinases. The Enzymes: Control by Phosphorylation. vol. 17, Part A:1986;43-111 Academic, New York.
25. Cho-Chung Y.S., Pepe S., Clair T., Budillon A., Nesterova M. cAMP-dependent protein kinase: role in normal and malignant growth. Crit. Rev. Oncol./Hematol. 21:1995;33-61.
26. Tortora G., Ciardiello F. Protein kinase A as target for novel integrated strategies of cancer therapy. Ann. N.Y. Acad. Sci. 968:2002;139-147.
27. Bradbury A.W., Carter D.C., Miller W.R., Cho-Chung Y.S., Clair T. Protein kinase A (PK-A) regulatory subunit expression in colorectal cancer and related mucosa. Br. J. Cancer. 69:1994;738-742.
28. Miller W.R., Watson D.M.A., Jack W., Chetty U., Elton R.A. Tumor cyclic AMP binding proteins: an independent prognostic factor for disease recurrence and survival in breast cancer. Breast Cancer Res. Treat. 26:1993;89-94.
29. Tortora G., Yokozaki H., Pepe S., Clair T., Cho-Chung Y.S. Differentiation of HL-60 leukemia cells by type I regulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. U. S. A. 88:1991;2011-2015.
30. Cho-Chung Y.S. Antisense oligonucleotide inhibition of serine/threonine kinases: an innovative approach to cancer treatment. Pharmacol. Ther. 82:1999;437-449.
31. Yokozaki H., Budillon A., Tortora G., Meissner S., Beaucage S.L., Miki K., Cho-Chung Y.S. An antisense oligodeoxynucleotide that depletes RIα subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells. Cancer Res. 53:1993;868-872.
32. Srivastava R.K., Srivastava A.R., Seth P., Agrawal S., Cho-Chung Y.S. Growth arrest and induction of apoptosis in breast cancer cells by antisense depletion of protein kinase A-RI alpha subunit: p53-independent mechanism of action. Mol. Cell. Biochem. 195:1999;25-36.
33. Alper O., Hacker N.F., Cho-Chung Y.S. Protein kinase A-Ialpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway. Oncogene. 18:1999;4999-5004.
34. Wang H., Cai Q., Zeng X., Yu D., Agrawal S., Zhang R. Antitumor activity and pharmacokenetics of a mixed-backbone antisense oligonucleotide targeted to the RIα subunit of protein kinase A after oral administration. Proc. Natl. Acad. Sci. U. S. A. 96:1999;13989-13994.
35. Cho-Chung Y.S., Nesterova M., Kondrashin A., Noguchi K., Srivastava R.K., Pepe S. Antisense-protein kinase A: a single-gene-based therapeutic approach. Antisense Nucleic Acid Drug Dev. 7:1997;217-223.
36. Cho Y.S., Kim M.K., Tan L., Srivastava R., Agrawal S., Cho-Chung Y.S. Protein kinase A RIα antisense inhibition of PC3M prostate cancer cell growth: bcl-2 hyperphosphorylation, Bax up-regulation, and Bad hypophosphorylation. Clin. Cancer Res. 8:2002;607-614.
37. Srivastava R.K., Srivastava A.R., Park Y.G., Agrawal S., Cho-Chung Y.S. Antisense depletion of RIalpha subunit of protein kinase A induces apoptosis and growth arrest in human breast cancer cells. Breast Cancer Res. Treat. 49:1998;97-107.
38. Tortora G., Clair T., Cho-Chung Y.S. An antisense oligodeoxynucleotide targeted against the type RIIβ regulatory subunit mRNA of protein kinase inhibits cAMP-induced differentiation in HL-60 leukemia cells without affecting phorbol ester effects. Proc. Natl. Acad. Sci. U. S. A. 87:1990;705-708.
39. Fennewald S.M., Rando R.F. Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides. J. Biol. Chem. 270:1995;21718-21721.
40. Guvakova M.A., Yakubov L.A., Vlodavsky I., Tonkinson J.L., Stein C.A. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270:1995;2620-2627.
41. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549.
42. Metelev V., Liszlewicz J., Agrawal S. Study of antisense oligonucleotide phosphorothioates containing segments of oligodeoxynucleotides and 2′-O-methyloligoribonucleotides. Bioorg. Med. Chem. Lett. 4:1994;2929-2934.
43. Monia B.P., Lesnik E.A., Gonzalez C., Lima W.F., McGee D. Evaluation of 2′-modified oligonucleotides containing 2′-deoxygaps as antisense inhibitors of gene expression. J. Biol. Chem. 268:1993;14514-14522.
44. Shibahara S., Mukai S., Morisawa H., Nakashima H., Kobayashi S., Yamamoto N. Inhibition of human immunodeficiency virus (HIV-1) replication by synthetic oligo-RNA derivatives. Nucleic Acids Res. 17:1989;239-252.
45. Tortora G., Bianco R., Damiano V., Fontanini G., De Placido S., Bianco A.R., Ciardiello F. Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production. Clin. Cancer Res. 6:2000;2506-2512.
46. Nesterova M., Noguchi K., Park Y.G., Lee Y.N., Cho-Chung Y.S. Compensatory stabilization of RIIβ protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense-directed down-regulation of protein kinase A RIα protein. Clin. Cancer Res. 6:2000;3434-3441.
47. Neary C.L., Cho-Chung Y.S. Nuclear translocation of the catalytic subunit of protein kinase A induced by an antisense oligonucleotide directed against the RIalpha regulatory subunit. Oncogene. 20:2001;8019-8024.
48. Ciardiello F., Pepe S., Bianco C., Baldassarre G., Ruggiero A., Selvam M.P., Bianco A.R., Tortora G. Down-regulation of RIα subunit of cAMP-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-Ha-ras and c-erbB-2 proto-oncogenes. Int. J. Cancer. 53:1993;438-443.
49. Ciardiello F., Tortora G., Kim N., Clair T., Ally S., Salomon D.S., Cho-Chung Y.S. 8-chloro-cAMP inhibits transforming growth factor α transformation of mammary epithelial cells by restoration of the normal mRNA patterns for cAMP-dependent protein kinase regulatory subunit isoforms which show disruption upon transformation. J. Biol. Chem. 265:1990;1016-1020.
50. Tortora G., Damiano V., Bianco C., Baldassarre G., Bianco A.R., Lanfrancone L., Pelicci P.G., Ciardello F. The RIα subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor. Oncogene. 14:1997;923-928.
51. Srivastava R.K., Srivastava A.R., Korsmeyer S.J., Nesterova M., Cho-Chung Y.S., Longo D.L. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol. Cell. Biol. 18:1998;3509-3517.
52. Yang W.L., Iacono L., Tang W.M., Chin K.V. Novel function of the regulatory subunit of protein kinase A: regulation of cytochrome c oxidase activity and cytochrome c release. Biochemistry. 37:1998;14175-14180.
53. Harada H., Becknell B., Wilm M., Huang L.J., Taylor S.S., Scott J.D., Korsmeyer S.J. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol. Cell. 3:1999;413-422.
54. Schena M., Shalon D., Davis R.W., Brown P.O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 270:1995;467-470.
55. Cho Y.S., Kim M.-K., Cheadle C., Neary C., Becker K.G., Cho-Chung Y.S. Antisense DNAs as multisite genomic modulators identified by DNA microarray. Proc. Natl. Acad. Sci. U. S. A. 98:2001;9819-9823.
56. Stein C.A. Does antisense exist? Nat. Med. 1:1995;1119-1121.
57. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U. S. A. 95:1998;14863-14868.
58. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., Powell J.I., Yang L., Marti G.E., Moore T., Hudson J. Jr., Lu L., Lewis D.B., Tibshirani R., Sherlock G., Chan W.C., Greiner T.C., Weisenburger D.D., Armitage J.O., Warnke R., Staudt L.M., Levy R., Wilson W., Grevor M.R., Byrd J.C., Botstein D., Brown P.O. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 403:2000;503-511.
59. Cho-Chung Y.S., Becker K.G. A genome-wide view of antisense. Nat. Biotechnol. 21:2003;492.
60. Budillon A., Cereseto A., Kondrashin A., Nesterova M., Merlo G., Clair T., Cho-Chung Y.S. Point mutation of the autophosphorylation site or in the nuclear location signal causes protein kinase A RIIβ regulatory subunit to lose its ability to revert transformed fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 92:1995;10634-10638.
61. Nesterova M.V., Yokozaki H., McDuffie L., Cho-Chung Y.S. Overexpression of RIIβ regulatory subunit of protein kinase A in human colon carcinoma cell induces growth arrest and phenotypic changes that are abolished by site-directed mutation of RIIβ Eur. J. Cancer. 235:1996;486-494.